Citations

Clear

3138 citation(s) found for "Smith, AM".

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
Dillmon, Melissa S., Levit, Laura A. , Moushey, E. Allyn, Alva, Ajjai , Blau, Sibel , Dickson, Natalie R. , Gönen, Mithat , González, Maria Magdalena, Hensold, Jack O. , Hinyard, Leslie , King, Tari A. , Lindsey, Stacie , Magnuson, Allison , Marron, Jonathan M. , Mcaneny, Barbara , McDonnell, Theresa Margaret, Nasso, S, Nowakowski, Grzegorz S. , Oettel, Kurt R., Patel, Manali I. , Patt, Debra A. , Perlmutter, Jane , Pickard, Todd , Rodriguez, Gladys , Rosenberg, Abby R. , Russo, Barry, Szczepanek, Connie M. , Smith, Cardinale B. , Teplinsky, Eleonora , Thota, Ramya , Zoň, Robin , Bourbeau, Brian , Foster, Shelagh E., Grubbs, Stephen, Hagerty, Karen L., Hurley, Patricia A. , Kamin, Deborah Y., Phillips, Jonathan , Schilsky, Richard L. , Burris, Howard A. , Hurley, Patricia , Rosenberg, Abby R , Pennell, Nathan A , Cannon, Timothy Lewis , Diehn, Maximilian , Mileham, Kathryn Finch , Srivastava, Piyush, Traina, Tiffany A , Bruinooge, Suanna S. , Schenkel, Caroline

Mayo Clinic

Journal of Clinical Oncology | December 8, 2020 | Volume: 39 | Issue: 2 | Pages: 155-169

10.1200/jco.20.02953 | PMID 33290128 Get It

This report presents the American Society of Clinical Oncology’s (ASCO’s) evaluation of the adaptations in care delivery, research operations, and regulatory oversight made in response to the coronavirus pandemic and presents recommendations for moving forward as the pandemic recedes. ASCO organized its recommendations for clinical research around five goals to ensure lessons learned from the COVID-19 experience are used to craft a more equitable, accessible, and efficient clinical research system that protects patient safety, ensures scientific integrity, and maintains data quality. The specific goals are: (1) ensure that clinical research is accessible, affordable, and equitable; (2) design more pragmatic and efficient clinical trials; (3) minimize administrative and regulatory burdens on research sites; (4) recruit, retain, and support a well-trained clinical research workforce; and (5) promote appropriate oversight and review of clinical trial conduct and results. Similarly, ASCO also organized its recommendations regarding cancer care delivery around five goals: (1) promote and protect equitable access to high-quality cancer care; (2) support safe delivery of high-quality cancer care; (3) advance policies to ensure oncology providers have sufficient resources to provide high-quality patient care; (4) recognize and address threats to clinician, provider, and patient well-being; and (5) improve patient access to high-quality cancer care via telemedicine. ASCO will work at all levels to advance the recommendations made in this report.
Returning negative results from large‐scale genomic screening: Experiences from the eMERGE III network
Finn, Kelsey Stuttgen , Aufox, Sharon , Bland, Harris T. , Halverson, Colin , Hebbring, Scott J. , Hoell, Christin , Jarvik, Gail P. , Leppig, Kathleen A. , Myers, Melanie F. , Prows, Cynthia A. , Rasouly, Hila Milo , Weisner, Georgia, Williams, Janet L. , Wynn, Julia , Smith, Maureen E. , Sharp, Richard R. , Halverson, Colin , Kullo, Iftikhar J , Myers, Melanie F , Sharp, Richard R , Bland, Sarah T , Milo Rasouly, Hila , Jarvik, Gail P , Hoell, Christin , Stuttgen, Kelsey , Lynch, John , Chung, Wendy K. , Holm, Ingrid A. , Kullo, Iftikhar J. , Singh, Rajbir

Mayo Clinic

American Journal of Medical Genetics Part A | December 8, 2020 | Volume: 185 | Issue: 2 | Pages: 508-516

10.1002/ajmg.a.62002 | PMID 36046768 Get It

AbstractPopulation‐based genomic screening has the potential to improve health outcomes by identifying genetic causes of disease before they occur. While much attention has been paid to supporting the needs of the small percentage of patients who will receive a life‐altering positive genomic screening result that requires medical attention, little attention has been given to the communication of negative screening results. As there are currently no best practices for returning negative genomic screening results, we drew on experiences across the electronic medical records and genomics (eMERGE) III Network to highlight the diversity of reporting methods employed, challenges encountered in reporting negative test results, and “lessons learned” across institutions. A 60‐item survey that consisted of both multiple choice and open‐ended questions was created to gather data across institutions. Even though institutions independently developed procedures for reporting negative results, and had very different study populations, we identified several similarities of approach, including but not limited to: returning results by mail, placing results in the electronic health record via an automated process, reporting results to participants' primary care provider, and providing genetic counseling to interested patients at no cost. Differences in procedures for reporting negative results included: differences in terminology used to describe negative results, definitions of negative results, guidance regarding the meaning of negative results for participants and their family members, and recommendations for clinical follow up. Our findings highlight emerging practices for reporting negative genomic screening results and highlight the need to create patient education and clinical support tools for reporting negative screening results.
Yoga training impacts physical function 12 months post intervention for care partners of those with mild cognitive impairment
Chandler, Melanie , Thomas, Colleen S. , Graff‐Radford, Michelle , Lucas, Pauline , Locke, Dona E.C. , Crook, Julia E. , Graff-Radford, Michelle R , Phatak, Vaishali , Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S7 | Pages: No page available

10.1002/alz.045418 Get It

AbstractBackgroundThe American Academy of Neurology Practice Guidelines recommends physical exercise to help maintain cognition in people with Mild Cognitive Impairment (pwMCI). We previously demonstrated yoga’s benefit in maintenance of memory related activities of daily living at one year follow‐up in pwMCI (Chandler et al., 2019), and yoga may be beneficial in offsetting a sense of burden in care partners at 12 months (Amofa et al., submitted). In this analysis, we sought to examine the impact of yoga training on physical performance in pwMCI and their care partners.MethodIn this multisite, randomized clinical trial, we enrolled 272 patients meeting National Institute on Aging–Alzheimer’s Association criteria for MCI and a care partner. The intervention program was modeled on the 10 day Mayo Clinic HABIT Healthy Action to Benefit Independence and Thinking® program. Of 5 possible interventions (memory compensation training, computerized cognitive training, yoga, patient and partner support groups, and wellness education), 1 of 5 interventions was randomly selected to be withheld for each intervention group, thus allowing us to examine comparative effectiveness. Participants and their partners had 1‐day booster sessions at 6 and 12 months after intervention. The Short Physical Performance Battery (SPPB), a measure of balance, gait speed, and repeated chair stands was used to assess physical function outcomes.ResultThere was a general pattern of physical decline on the SPPB over the year in pwMCI, regardless of yoga training (d=‐0.04, p=0.78) (Figure 1, Panel A). Among care partners, those randomized to the no yoga group had a worse decline in physical function compared to those receiving yoga (d=‐0.31, p=0.034) (Figure 1, Panel B). While not reaching statistical significance in subgroup comparisons, yoga training tended to have a greater effect on SPPB than computerized cognitive training (d = 0.35, p = .06) or wellness education (d = 0.32, p =.09) (Table 1).ConclusionParticipation in yoga had a positive impact on physical performance outcomes at one year for care partners, but did not counteract general physical decline in pwMCI.
The impact of patient and partner personality traits on learning success for a cognitive rehabilitation intervention for patients with MCI
Devick, Katrina L. , Khayoun, Renata, Cuc, Andrea , Shandera‐Ochsner, Anne L., Francone, Andrea , Chandler, Melanie , Locke, Dona E.C. , Smith, Glenn E.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S7 | Pages: No page available

10.1002/alz.043672 Get It

AbstractBackgroundOne nonpharmacological intervention for persons with amnestic Mild Cognitive Impairment (MCI) is development of a compensatory memory notebook/planner system. De Wit et al. (2019) showed that global cognitive status is the primary predictor of learning success with training on a memory notebook system and that learning success predicts ongoing adherence to the tool. The purpose of our work is to validate their analysis in a new sample and evaluate whether or not patient or partner personality traits predict learning success over and above that explained by cognitive status.MethodTraining in the Memory Support System (MSS) is one component of the multi‐disciplinary behavioral intervention program called Healthy Action to Benefit Independence and Thinking (HABIT) offered at Mayo Clinic. 183 patient and partner dyads completed the HABIT program and enrolled in our IRB approved ongoing research registry to allow use of their clinical data for research purposes. Personality traits were measured with the self‐report Ten Item Personality Inventory (TIPI) based on the five‐factor model of personality (Agreeableness, Conscientiousness, Emotional Stability, Openness, and Extraversion) completed by both the patient and the partner. For our analyses, we fit logistic regression models to predict full MSS mastery at the end of the two‐week program and dichotomized TIPI into “high” or “low” for each trait based on its median (low was the reference group).ResultConsistent with De Wit et al. (2019), global cognitive status again was the only significant predictor of MSS learning mastery when considering age, education, baseline depression score and baseline global cognitive status (Table 2). When adding patient personality traits, only openness significantly added to the model with higher openness predicting learning success (Table 3). Adding both patient and partner personality traits resulted in a significant interaction between patient and partner openness (Table 4). The direction of this interaction indicates that learning success is highest when either the partner or patient is high in openness (but not both).ConclusionHigh openness to experience in the patient with MCI or their partner (but not both) significantly improves learning success for a cognitive rehabilitation memory support tool in patients with MCI.
Possible Influence of Antibiotic Therapy on Usefulness of Metabolic Inhibition Test for Diagnosis of Mycoplasma pneumoniae Infections
Smith, Thomas F., Herrmann, Ernest C.

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 21 | Issue: 1 | Pages: 160-161

10.1128/am.21.1.160-161.1971 | PMID 5099762 Get It

Certain antibiotics, if in serum, simulate specific antibody in the metabolic inhibition test for diagnosis of Mycoplasma pneumoniae infections. This effect is not eliminated by presence of serum or heat treatment.
Tetrazolium Agar Overlay in Test for Mycoplasma pneumoniae
Woods, Larry L., Smith, Thomas F.

Mayo Clinic

Applied Microbiology | December 5, 2020 | Volume: 24 | Issue: 1 | Pages: 148-149

10.1128/am.24.1.148-149.1972 | PMID 4560467 Get It

In this rapid presumptive test for Mycoplasma pneumoniae , subculture is not required, and tetrazolium reduction is evident in 1 hr or less.
Characterizing the complexity of frontal endoscopic sinus surgery: a multi‐institutional, prospective, observational trial
Levy, Joshua M. , Smith, Kristine A. , Yao, William C. , Halderman, Ashleigh A. , Oakley, Gretchen M. , Brunworth, Joseph D., Alt, Jeremiah A. , Chen, Philip G , Levy, Joshua M , Choby, Garret , Smith, Kristine , Yao, William C , Alt, Jeremiah A , Chen, Philip G. , Choby, Garret

Mayo Clinic

International Forum of Allergy & Rhinology | December 4, 2020 | Volume: 11 | Issue: 5 | Pages: 941-945

10.1002/alr.22746 | PMID 33275315 Get It

Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria
Metzger, Monika L. , Milgrom, Sarah A. , Advani, Ranjana H. , Bakst, Richard L. , Dabaja, Bouthaina S. , Flowers, Christopher R. , Ha, Chul S. , Mansur, David B., Roberts, Kenneth B. , Smith, Sonali M. , Terezakis, Stephanie , Advani, Ranjana H , Ballas, Leslie , Hoppe, Bradford S. , Pinnix, Chelsea C. , Plastaras, John Peter , Constine, Louis S

Mayo Clinic

Leukemia & Lymphoma | December 4, 2020 | Volume: 62 | Issue: 5 | Pages: 1057-1065

10.1080/10428194.2020.1852559 | PMID 33274673 Get It

EXTH-01. INHIBITION OF DNA-PKcs BY M3814 POTENTIATES EFFICACY OF IONIZING RADIATION IN PATIENT-DERIVED XENOGRAFTS OF MELANOMA BRAIN METASTASES
Ji, Jianxiong , Sarkaria, Paige P., Swanson, Katelyn, Mohammad, Afroz S., He, Lihong , Hu, Zeng , Zhao, Yu , Connors, Margaret A. , Porath, Kendra A. , Carlson, Brett L. , Kitange, Gaspar J. , Elmquist, William F. , Smith, Emily J. , Mladek, Ann C. , Talele, Surabhi , Zhang, Wenjuan , Chen, Jiajia , Bakken, Katrina K. , Dragojevic, Sonja , Gupta, Shiv K. , Burgenske, Danielle M. , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | December 4, 2020 | Volume: 22 | Issue: Supplement_2 | Pages: ii86-ii86

10.1093/neuonc/noaa215.355 Get It

Abstract Radio-resistance mechanisms limit the benefit of radiation therapy (RT) for melanoma brain metastases. A key pathway for radiation-induced DNA double-strand break repair is non-homologous end joining, which is critically mediated by DNA-dependent protein kinase (DNA-PKcs). Here we evaluated radio-sensitizing effects of M3814, a selective oral inhibitor of DNA-PKcs, in patient-derived xenografts (PDXs) of melanoma brain metastases. In a clonogenic survival assay, M3841 augmented RT-induced killing of M12 cells at concentrations of ≥300 nM, and a minimum of 16 h exposure with ~300 nM M3814 was required for effective sensitization. M3814 inhibited RT-induced (5 Gy) auto-phosphorylation of serine-2056 of DNA-PKcs in primary cultures of M12, M15 and M27 PDX lines. Interestingly, inhibition of RT-induced DNA-PKcs by M3814 coincided with increased KAP1 phosphorylation, a DNA damage signaling regulated via ATM. Persistent γH2AX foci were observed in 28% M12 cells at 24 hours after co-treatment with M3814 and RT as compared to 12% cells following RT alone. In vivo pharmacokinetic analysis after single oral dose of 20 mg/kg M3814, showed reasonably short half-life (~2.44 hours) and poor brain distribution in wild-type FBV mice (Kpuu, 0.027). Consistent with an efflux liability, brain distribution of M3814 in triple knockout mice for BCRP/MDR1A/B was ~11 fold higher (Kpuu, 0.215). Compared to normal brain, much higher M3814 concentrations were detected in intracranially implanted M12 tumors (~23 fold and ~20 fold) 2 and 6 hours after a single oral dose of 50mg/kg respectively. The relative exclusion of M3814 from normal brain as compared to brain metastases suggests that this drug may have a favorable toxicity profile when combined with radiation for treatment of melanoma brain metastases, and this hypothesis is being tested in ongoing efficacy studies.
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis
Gerds, Aaron T. , Savona, Michael R. , Scott, Bart L. , Egyed, Miklós , Harrison, Claire , Yacoub, Abdulraheem , Vannucchi, Alessandro M. , Mead, Adam J. , O’Sullivan, Jennifer , García‐Gutiérrez, Valentín , Rampal, Raajit K. , Miller, Carole B., Palmer, Jeanne , Buckley, Sarah , Mould, Diane R. , Ito, Kaori , Tyavanagimatt, Shanthakumar , Roman‐Torres, Karisse, Devineni, Sri, Craig, Adam R., Vannucchi, Alessandro M , Gerds, Aaron T , Savona, Michael R , Mead, Adam J , Talpaz, Moshe , Kiladjian, Jean‐Jacques , Bose, Prithviraj , Oh, Stephen T. , Smith, Jennifer A. , Mascarenhas, John

Mayo Clinic

Blood Advances | December 3, 2020 | Volume: 4 | Issue: 22 | Pages: 5825-5835

10.1182/bloodadvances.2020003314 | PMID 33232476 Get It

Abstract PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduction in the 7-component total symptom score (TSS) through week 24. Of 161 patients, 73% were intolerant of and 76% had become resistant to ruxolitinib; 50% met criteria for both. Severe thrombocytopenia (platelet count <50 × 103/μL) was present in 44%. SVR rates were highest with 200 mg twice per day (100 mg once per day, 0%; 100 mg twice per day, 1.8%; 200 mg twice per day, 9.3%), particularly among patients with baseline platelet counts <50 × 103/μL (17%; 4 of 24). Although TSS response rate was similar across doses (100 mg once per day, 7.7%; 100 mg twice per day, 7.3%; 200 mg twice per day, 7.4%), median percent reduction in TSS suggested a dose-response relationship (–3%, −16%, and −27%, respectively). Pharmacokinetic and pharmacodynamic modeling based on all available data showed greatest SVR and TSS reduction at 200 mg twice per day compared with lower doses. Common adverse events were gastrointestinal events, thrombocytopenia, and anemia. There was no excess of grade ≥3 hemorrhagic or cardiac events at 200 mg twice per day. Pacritinib 200 mg twice per day demonstrated clinical activity and an acceptable safety profile and was selected as the recommended dose for a pivotal phase 3 study in patients with myelofibrosis and severe thrombocytopenia. This trial was registered at www.clinicaltrials.gov as #NCT03165734.